OrbiMed’s Illumina ILMN Stock Holding History

OrbiMed’s Portfolio ILMN Stock Details ILMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-102,800	Closed	-$11.1M	–	144
2013 Q4	$11.1M	Buy	+102,800	New	+$9.42M	0.16%	79

Other funds holding ILMN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

OrbiMed's ILMN Position: Q1 2024 in Review

OrbiMed sold out of Illumina (ILMN) in Q1 2024, closing a stake of 31,148 shares — an estimated $4.22M sold.

OrbiMed first reported a position in ILMN in Q2 2013 and held it in 28 quarters. The position peaked at $273M in Q4 2014. 795 funds tracked by Wall St. Rank hold ILMN as of Q1 2024.

OrbiMed reported no remaining Illumina position as of Q1 2024 after selling out during the quarter.
OrbiMed sold 31,148 Illumina shares in Q1 2024, an estimated $4.22M.
OrbiMed first reported a position in Illumina in Q2 2013 and held it in 28 quarters.
OrbiMed's Illumina position peaked at $273M in Q4 2014.
795 funds tracked by Wall St. Rank held Illumina as of Q1 2024.

Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.